163 related articles for article (PubMed ID: 9781173)
1. [Anomalies of phosphate and calcium metabolism in chronic renal insufficiency].
Drüeke TB
Rev Prat; 1998 Jun; 48(11):1207-12. PubMed ID: 9781173
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Disorders of calcium metabolism in kidney failure].
Ritz E; Krempien B; Andrassy K
Med Klin; 1972 Sep; 67(36):1129-32. PubMed ID: 4561354
[No Abstract] [Full Text] [Related]
4. [Peculiar problems of phosphocalcium metabolism in chronic renal insufficiency].
Drüeke T
Rev Prat; 1989 Apr; 39(11):954-8. PubMed ID: 2717868
[TBL] [Abstract][Full Text] [Related]
5. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
Ito H; Kinugasa E
Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
[TBL] [Abstract][Full Text] [Related]
7. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
9. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of surgical parathyroidectomy for secondary hyperparathyroidism in renal dialysis patients in Qatar.
Rashed A; Fahmi M; ElSayed M; Aboud O; Asim M
Transplant Proc; 2004; 36(6):1815-7. PubMed ID: 15350484
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
12. Dietary and pharmacological control of calcium and phosphate metabolism in dialysis patients.
Bover J; Andrés E; Lloret MJ; Aguilar A; Ballarín J
Blood Purif; 2009; 27(4):369-86. PubMed ID: 19295200
[TBL] [Abstract][Full Text] [Related]
13. Secondary hyperparathyroidism in chronic renal failure.
Wills MR; Savory J
Ann Clin Lab Sci; 1981; 11(3):252-61. PubMed ID: 6264838
[TBL] [Abstract][Full Text] [Related]
14. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
Goodman WG
Semin Dial; 2004; 17(3):209-16. PubMed ID: 15144547
[TBL] [Abstract][Full Text] [Related]
15. Klotho gene, phosphocalcic metabolism, and survival in dialysis.
Torres PU; Prié D; Beck L; De Brauwere D; Leroy C; Friedlander G
J Ren Nutr; 2009 Jan; 19(1):50-6. PubMed ID: 19121771
[TBL] [Abstract][Full Text] [Related]
16. [A case of primary hypoparathyroidism and hypothyroidism co-existing with chronic renal failure].
Bednarek-Tupikowska G; Kuliczkowska J; Filus A
Pol Merkur Lekarski; 2005 Apr; 18(106):433-5. PubMed ID: 16161929
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D analogs as therapeutic agents: a clinical study update.
Wu-Wong JR; Tian J; Goltzman D
Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
[TBL] [Abstract][Full Text] [Related]
18. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
[TBL] [Abstract][Full Text] [Related]
20. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
